WiseGuyReports.com adds“Cancer Genome Sequencing 2016 Market
Share,Size,Trends and Forecast to 2022 Market Research Report”reports to its database.
COMPLETE
REPORT DETAILS @
https://www.wiseguyreports.com/reports/world-cancer-genome-sequencing-market-opportunities-and-forecasts-2014-2022
Cancer genome sequencing refers to a method used to
identify the complete DNA or RNA sequence of cancer cells based on the
sequencing of a single, homogeneous or heterogeneous group of tumor cells. It
is a laboratory technique that characterizes DNA or RNA sequences of primary
tumor tissue, the tumor micro environment (such as stromal / fibroblast cells),
adjacent or distal normal tissue, or metastatic tumor sites. This technique
generates information related to identification of nucleotide bases (DNA or
RNA), mutation status, copy number and sequence variants, as well as structural
variations including fusion genes and chromosomal translocations. This
technique has proved to be a breakthrough in the fight against cancer as it
assists in individualization of treatment. Development of new methods and
exponential decrease in genome sequencing cost are fueling the market growth.
Global cancer genome sequencing market is expected grow with a healthy CAGR due
to technological advances and entry of new market players. Agilent
Technologies, GE Healthcare Life Sciences, Johnson & Johnson, LI-COR
Biosciences (Lincoln, NE), Abbott Laboratories, Beckman Coulter (Fullerton,
CA), Bayer Corporation, Hamilton Thorne Biosciences, Integrated DNA
Technologies, Microchip Biotechnologies, Myriad Genetics, Commonwealth
Biotechnologies, ZS Genetics, and Pacific Biosciences are some of the key
players of this market.
For more information or any query mail at
sales@wiseguyreports.com
The global cancer genome sequencing market is segmented on the basis of
technology and geography. The currently technologies used include second
generation and third generation platforms. Second generation technology
platforms include SOLiD sequencing (by ABI), Pyro-sequencing (by Roche) and
Bridge amplification sequencing technology (by Illumina). Third generation
technology platform includes Single Molecule Real Time (SMRT) sequencing (by
Pacific Biosciences), Ion semiconductor sequencing, Nanopore sequencing (by
Oxford) and fluorescent resonant energy transfer (FRET) sequencing (by VisiGen
biotechnologies). Geographically, the global cancer genome sequencing market is
segmented into North America, Europe, Asia-Pacific and LAMEA. North America
dominates the global cancer genome sequencing market due to availability of
advanced technologies and a skilled workforce. This market is driven by whole
genome sequencing coupled with bioinformatics based sequencing technologies
which provide personalized treatments for cancer.
KEY
BENEFITS
This report offers the following benefits in particular:
Pin-point analysis of geographic segments helps to identify opportunities
for growth within the global cancer genome sequencing market
Porter’s Five Forces analysis examines the competitive structure of the global cancer genome sequencing market and would assist market strategists in their decision-making process.
In-depth coverage of the global cancer genome sequencing market including drivers, restraints and opportunities would help professionals to better understand market behavior
Detailed study of the strategies of key leaders, partnerships and acquisitions in the global cancer genome sequencing market would be informative for professionals in the corporate sector
Porter’s Five Forces analysis examines the competitive structure of the global cancer genome sequencing market and would assist market strategists in their decision-making process.
In-depth coverage of the global cancer genome sequencing market including drivers, restraints and opportunities would help professionals to better understand market behavior
Detailed study of the strategies of key leaders, partnerships and acquisitions in the global cancer genome sequencing market would be informative for professionals in the corporate sector
REQUEST
FOR TABLE OF CONTENTS @ https://www.wiseguyreports.com/request-toc/world-cancer-genome-sequencing-market-opportunities-and-forecasts-2014-2022
KEY
MARKET SEGMENTS
The global cancer genome sequencing market is segmented into two broad
categories: technology and geography.
MARKET
BY TECHNOLOGY
Second Generation Technology Platforms
SOLiD sequencing (by ABI)
Pyro-sequencing (by Roche)
Bridge amplification sequencing technology (by Illumina)
Third Generation Technology Platforms
Single Molecule Real Time (SMRT) sequencing (by Pacific Biosciences)
Ion semiconductor sequencing.
Nanopore sequencing (by Oxford)
fluorescent resonant energy transfer (FRET) sequencing (by VisiGen biotechnologies)
SOLiD sequencing (by ABI)
Pyro-sequencing (by Roche)
Bridge amplification sequencing technology (by Illumina)
Third Generation Technology Platforms
Single Molecule Real Time (SMRT) sequencing (by Pacific Biosciences)
Ion semiconductor sequencing.
Nanopore sequencing (by Oxford)
fluorescent resonant energy transfer (FRET) sequencing (by VisiGen biotechnologies)
MARKET BY GEOGRAPHY
North America
Europe
Asia-Pacific
LAMEA
Europe
Asia-Pacific
LAMEA
RESEARCH
METHODOLOGY
With collective industry experience of about 200 years of its analysts
and experts, Allied Market Research (AMR) encompasses most infallible research
methodology for its market intelligence and industry analysis. We do not only
engrave the deepest levels of markets but also sneak through its slimmest
details for the purpose of our market estimates and forecasts. Our approach
helps in building greater market consensus view for size, shape and industry
trends within each industry segment. We carefully factor in industry trends and
real developments for identifying key growth factors and future course of the
market. Our research proceeds are the resultant of high quality data, expert
views and analysis and high value independent opinions. Our research process is
designed to deliver balanced view of the global markets and allow stakeholders
to make informed decisions.
We offer our clients exhaustive research and analysis based on wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics and regional intelligence. Our in-house industry experts play instrumental role in designing analytic tools and models, tailored to the requirements of particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of our recommendations and advice. With AMR’s calibrated research process and 360` degree data-evaluation methodology, our clients are assured of receiving:
We offer our clients exhaustive research and analysis based on wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics and regional intelligence. Our in-house industry experts play instrumental role in designing analytic tools and models, tailored to the requirements of particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of our recommendations and advice. With AMR’s calibrated research process and 360` degree data-evaluation methodology, our clients are assured of receiving:
- Consistent, valuable, robust and actionable data & analysis that
can easily be referenced for strategic business planning
- Technologically sophisticated and reliable insights through well
audited and veracious research methodology
- Sovereign research proceeds that present a tangible depiction of
marketplace
CONTINUE…….
For more information or any query mail at sales@wiseguyreports.com
Contact
Us:
NORAH TRENT
Partner
Relations & Marketing Manager
sales@wiseguyreports.com
www.wiseguyreports.com
Ph:
+1-646-845-9349 (US)
Ph:
+44 208 133 9349 (UK)
No comments:
Post a Comment